IRIS
GERRATANA, Lorenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.041
AS - Asia 3.236
EU - Europa 1.678
SA - Sud America 504
AF - Africa 64
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 3
Totale 11.530
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.930
SG - Singapore 1.649
CN - Cina 610
BR - Brasile 423
IT - Italia 348
HK - Hong Kong 346
DE - Germania 336
VN - Vietnam 263
RU - Federazione Russa 196
UA - Ucraina 177
IN - India 127
GB - Regno Unito 100
IE - Irlanda 80
FI - Finlandia 70
SE - Svezia 67
CA - Canada 57
TR - Turchia 44
KR - Corea 43
FR - Francia 38
PL - Polonia 38
AT - Austria 34
BE - Belgio 34
NL - Olanda 33
JP - Giappone 32
CZ - Repubblica Ceca 30
AR - Argentina 29
MX - Messico 27
ZA - Sudafrica 26
BD - Bangladesh 21
ES - Italia 20
CH - Svizzera 16
LT - Lituania 16
RO - Romania 15
IR - Iran 12
CO - Colombia 11
EC - Ecuador 11
ID - Indonesia 11
IQ - Iraq 11
VE - Venezuela 10
AE - Emirati Arabi Uniti 8
EG - Egitto 8
PY - Paraguay 8
PK - Pakistan 7
MA - Marocco 6
AZ - Azerbaigian 5
CL - Cile 5
EE - Estonia 5
IL - Israele 5
JM - Giamaica 4
KZ - Kazakistan 4
LA - Repubblica Popolare Democratica del Laos 4
LB - Libano 4
LV - Lettonia 4
NO - Norvegia 4
SA - Arabia Saudita 4
TG - Togo 4
AL - Albania 3
AM - Armenia 3
BO - Bolivia 3
DK - Danimarca 3
DZ - Algeria 3
EU - Europa 3
HN - Honduras 3
NI - Nicaragua 3
PA - Panama 3
SN - Senegal 3
TN - Tunisia 3
UY - Uruguay 3
AU - Australia 2
BB - Barbados 2
BG - Bulgaria 2
CI - Costa d'Avorio 2
GE - Georgia 2
GR - Grecia 2
HU - Ungheria 2
KE - Kenya 2
KG - Kirghizistan 2
MY - Malesia 2
OM - Oman 2
RS - Serbia 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
UZ - Uzbekistan 2
AF - Afghanistan, Repubblica islamica di 1
BH - Bahrain 1
BS - Bahamas 1
BY - Bielorussia 1
BZ - Belize 1
CM - Camerun 1
CV - Capo Verde 1
CW - ???statistics.table.value.countryCode.CW??? 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GP - Guadalupe 1
GT - Guatemala 1
HT - Haiti 1
JO - Giordania 1
KH - Cambogia 1
KW - Kuwait 1
LC - Santa Lucia 1
Totale 11.513
Salva come PNG Salva come JPEG
Città #
Ashburn 835
Fairfield 716
Singapore 700
Chandler 446
Woodbridge 346
Hong Kong 344
Seattle 305
Beijing 283
Houston 277
Wilmington 242
Cambridge 227
Ann Arbor 207
Boardman 145
Los Angeles 136
Frankfurt am Main 130
Dearborn 115
New York 108
Jacksonville 98
Princeton 76
Dublin 75
Dallas 74
Ho Chi Minh City 74
Munich 68
Buffalo 65
Dong Ket 64
Udine 54
Hefei 50
Hanoi 44
São Paulo 44
Redondo Beach 42
Seoul 42
San Diego 39
Warsaw 37
Washington 34
Montreal 31
Tokyo 30
Brussels 29
Santa Clara 29
Izmir 27
Martignacco 26
Redmond 26
Stockholm 26
Brno 25
Ogden 24
Denver 23
Des Moines 23
London 22
Turku 22
Nuremberg 21
Phoenix 21
Brooklyn 20
Chennai 20
Orem 20
Belluno 18
Johannesburg 18
Boston 16
Chicago 16
Guangzhou 16
Poplar 16
Vienna 16
Zurich 15
Helsinki 14
Milan 14
Lappeenranta 13
Mexico City 13
Rome 13
Falls Church 12
Nanjing 12
Norwalk 12
San Francisco 12
Düsseldorf 11
Hyderabad 11
Mumbai 11
Shanghai 11
Trieste 11
Ankara 10
Belo Horizonte 10
Council Bluffs 10
Da Nang 10
Jinan 10
Lauterbourg 10
Leawood 10
Naples 10
The Dalles 10
Amsterdam 9
Arezzo 9
Augusta 9
Charlotte 9
Timisoara 9
Toronto 9
City of London 8
Manchester 8
Xi'an 8
Atlanta 7
Biên Hòa 7
New Delhi 7
Newark 7
San Jose 7
Brasília 6
Cairo 6
Totale 7.523
Salva come PNG Salva come JPEG
Nome #
In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis 205
The SLICE study: The prognostic role of visceral fat in metastatic colorectal cancer 197
First steps in the definition of a prognostic score based on MGMT methylation status in patients with glioblastoma 182
MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme 178
Luminal-like HER2-negative stage IA breast cancer: A multicenter retrospective study on long-term outcome with propensity score analysis 176
Neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios in breast cancer 169
Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme 161
Androgen receptor in estrogen receptor positive breast cancer: Beyond expression 161
Pattern of metastasis and outcome in patients with breast cancer 161
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 160
Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach 159
Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker 158
Emerging Role of Genomics and Cell-Free DNA in Breast Cancer 157
Measures of outcome in metastatic breast cancer: insights from a real-world scenario. 152
Caring for cancer survivors: perspectives of oncologists, general practitioners and patients in Italy 149
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 149
Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside 148
Treatment of metastatic breast cancer in a real-world scenario: Is progression-free survival with first line predictive of benefit from second and later lines? 144
APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC 144
Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy 143
Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example 141
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? 141
The role of sidedness in second-line therapy for RAS wild-type colorectal cancer: a network meta-analysis (NMA) 135
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 134
A risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients 132
Do platinum salts fit all triple negative breast cancers? 131
Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey 130
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC 130
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 130
Role of Bruton's Tyrosine Kinase in Stage III Colorectal Cancer 126
Monitoring metastatic breast cancer (M-MBC) during treatment: a GIM (Gruppo Italiano Mammella) survey 125
Determinants of Last-line Treatment in Metastatic Breast Cancer 124
Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle 123
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 123
Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer 123
Monocyte-to-lymphocyte ratio in metastatic colorectal cancer: Prognostic role evaluation and cut-off definition 122
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 119
International expert consensus on the clinical integration of circulating tumor cells in solid tumors 118
Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations. 115
Hype or hope? The strange case of platinum salts’ renaissance in breast cancer 115
Small luminal-like breast cancer: determinants of adjuvant chemotherapy use 115
Complementary and alternative medicine in oncology [Le terapie alternative e complementari in oncologia] 114
Lactate dehydrogenase as a prognostic biomarker in patients with hormone receptor-positive metastatic breast cancer treated with palbociclib: An exploratory cohort study 114
Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors 113
The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients 113
Factors affecting patient's perception of anticancer treatments side-effects: an observational study. 112
CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer 112
Low dose CT scan screening versus empiric surveillance in asbestos exposed subjects: Update of ATOM 002 study 109
Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer 107
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis 105
1781P Feasibility of an automated data solution for Binary Alignment Map (BAM) files generated through next generation sequencing (NGS) of circulating tumor DNA (ctDNA) 104
Abstract PD10-01: Impact of ESR1 mutations on Selective Estrogen Receptor Degraders and Modulators: an integrated liquid-biopsy and pharmacodynamics approach 103
Risk factors and survival outcomes in patients with brain metastases from breast cancer 103
Neutrophil-to-lymphocyte ratio in metastatic breast cancer patients: relationship with tumor characteristics and survival 101
Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation 99
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper 98
Bevacizumab or PARP-Inhibitors maintenance therapy for platinum-sensitive recurrent ovarian cancer: A network meta-analysis 98
Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis 96
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer? 95
The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer 95
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic non-squamous NSCLC 94
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure 92
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer 89
Image Analysis of Circulating Tumor Cells and Leukocytes Predicts Survival and Metastatic Pattern in Breast Cancer Patients 87
null 84
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer 83
Homophilic CD44 interactions mediate tumor cell aggregation and polyclonal metastasis in patient-derived breast cancer models 83
Use and perception of complementary and alternative medicine among cancer patients: the CAMEO-PRO study: Complementary and alternative medicine in oncology 82
Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer 82
Longitudinal dynamics of circulating tumor cells and circulating tumor DNA for treatment monitoring in metastatic breast cancer 80
The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells 78
Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC) 78
Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China 75
Circulating tumor cell clusters are frequently detected in women with early-stage breast cancer 74
Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study 73
Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot study 72
A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer 72
Time to surgery after neoadjuvant chemotherapy for early breast cancer 71
Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: A proof of principle study on endocrine resistance profiling 70
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy 66
The puzzling clinical presentation of fluoropyrimidines cardiotoxicity 66
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long? 66
Cellular residual disease (CRD) in early breast cancer –Expanding the concept of minimal residual disease monitoring? 66
BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy 64
Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method 62
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer 62
Liquid biopsy in triple-negative breast cancer: unlocking the potential of precision oncology 61
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways 61
Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approach 60
Body mass index impacts adverse events and drug plasma concentration: should dose intensity be included in the palbociclib equation? 57
The use of liquid biopsy in early breast cancer: clinical evidence and future perspectives 57
Integration of Cellular and Humoral Immune Responses as an Immunomonitoring Tool for SARS-CoV-2 Vaccination in Healthy and Fragile Subjects 56
Longitudinal profiling of hormone receptor positive, HER2 negative metastatic breast cancer through droplet digital PCR-based circulating tumor DNA fragmentomics 56
Liquid Biopsy, an Everchanging Balance between Clinical Utility and Emerging Technologies 56
Editorial: Cancer evolution: From biological insights to therapeutic opportunities 55
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them 54
Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer 53
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 51
A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain Metastases 51
Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer 51
Totale 10.646
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.066
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.066
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021689 0 0 0 0 0 72 85 143 81 69 108 131
2021/2022753 88 69 15 14 14 40 46 25 20 107 221 94
2022/2023928 87 101 28 124 99 212 3 72 125 10 48 19
2023/2024715 45 29 56 30 118 193 9 19 43 25 30 118
2024/20252.566 130 158 97 107 186 119 175 145 315 172 413 549
2025/20263.449 576 516 382 562 867 546 0 0 0 0 0 0
Totale 11.983